Daiichi Sankyo Triples Down on Immuno-Oncology Collaboration with Zymeworks

Zymeworks and Daiichi Sankyo said they have expanded their two-year-old immuno-oncology collaboration focused on bispecific antibodies, more than tripling the value of their partnership to nearly $485 million.The companies said they signed a second agreement, under which Daiichi Sankyo will acquire licenses to Zymeworks’ Azymetric™ and EFECT™ technology platforms to develop two additional bispecific antibody therapeutics.Azymetric is designed to enable the transformation of mon